Literature DB >> 24145366

Rescue of recombinant Newcastle disease virus from cDNA.

Juan Ayllon1, Adolfo García-Sastre, Luis Martínez-Sobrido.   

Abstract

Newcastle disease virus (NDV), the prototype member of the Avulavirus genus of the family Paramyxoviridae(1), is a non-segmented, negative-sense, single-stranded, enveloped RNA virus (Figure 1) with potential applications as a vector for vaccination and treatment of human diseases. In-depth exploration of these applications has only become possible after the establishment of reverse genetics techniques to rescue recombinant viruses from plasmids encoding their complete genomes as cDNA(2-5). Viral cDNA can be conveniently modified in vitro by using standard cloning procedures to alter the genotype of the virus and/or to include new transcriptional units. Rescue of such genetically modified viruses provides a valuable tool to understand factors affecting multiple stages of infection, as well as allows for the development and improvement of vectors for the expression and delivery of antigens for vaccination and therapy. Here we describe a protocol for the rescue of recombinant NDVs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145366      PMCID: PMC3939320          DOI: 10.3791/50830

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  36 in total

Review 1.  Reverse genetics of mononegavirales.

Authors:  K K Conzelmann
Journal:  Curr Top Microbiol Immunol       Date:  2004       Impact factor: 4.291

2.  Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense.

Authors:  A Kato; Y Sakai; T Shioda; T Kondo; M Nakanishi; Y Nagai
Journal:  Genes Cells       Date:  1996-06       Impact factor: 1.891

3.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

4.  At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells.

Authors:  M Kozak
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

5.  Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.

Authors:  L S Wyatt; B Moss; S Rozenblatt
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

6.  The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA.

Authors:  P Calain; L Roux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence.

Authors:  B P Peeters; O S de Leeuw; G Koch; A L Gielkens
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

8.  Recovery of infectious human parainfluenza virus type 3 from cDNA.

Authors:  A P Durbin; S L Hall; J W Siew; S S Whitehead; P L Collins; B R Murphy
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

9.  Recombinant vesicular stomatitis viruses from DNA.

Authors:  N D Lawson; E A Stillman; M A Whitt; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

10.  Infectious rabies viruses from cloned cDNA.

Authors:  M J Schnell; T Mebatsion; K K Conzelmann
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

View more
  12 in total

1.  Recombinant Newcastle disease virus expressing H9 HA protects chickens against heterologous avian influenza H9N2 virus challenge.

Authors:  Abdou Nagy; Jinhwa Lee; Ignacio Mena; Jamie Henningson; Yuhao Li; Jingjiao Ma; Michael Duff; Yonghai Li; Yuekun Lang; Jianmei Yang; Fatma Abdallah; Juergen Richt; Ahmed Ali; Adolfo García-Sastre; Wenjun Ma
Journal:  Vaccine       Date:  2016-04-18       Impact factor: 3.641

2.  Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.

Authors:  James Duehr; Teddy John Wohlbold; Lisa Oestereich; Veronika Chromikova; Fatima Amanat; Madhusudan Rajendran; Sergio Gomez-Medina; Ignacio Mena; Benjamin R tenOever; Adolfo García-Sastre; Christopher F Basler; Cesar Munoz-Fontela; Florian Krammer
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

3.  PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

Authors:  Dmitriy Zamarin; Jacob M Ricca; Svetlana Sadekova; Anton Oseledchyk; Ying Yu; Wendy M Blumenschein; Jerelyn Wong; Mathieu Gigoux; Taha Merghoub; Jedd D Wolchok
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

4.  Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice.

Authors:  Irene González-Domínguez; Jose Luis Martínez; Stefan Slamanig; Nicholas Lemus; Yonghong Liu; Tsoi Ying Lai; Juan Manuel Carreño; Gagandeep Singh A; Gagandeep Singh B; Michael Schotsaert; Ignacio Mena; Stephen McCroskery; Lynda Coughlan; Florian Krammer; Adolfo García-Sastre; Peter Palese; Weina Sun
Journal:  bioRxiv       Date:  2022-03-22

5.  Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models.

Authors:  Aryana Javaheri; Yonina Bykov; Ignacio Mena; Adolfo García-Sastre; Sara Cuadrado-Castano
Journal:  Cancer Res Commun       Date:  2022-07-07

6.  Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.

Authors:  Irene González-Domínguez; Jose Luis Martínez; Stefan Slamanig; Nicholas Lemus; Yonghong Liu; Tsoi Ying Lai; Juan Manuel Carreño; Gagandeep Singh; Gagandeep Singh; Michael Schotsaert; Ignacio Mena; Stephen McCroskery; Lynda Coughlan; Florian Krammer; Adolfo García-Sastre; Peter Palese; Weina Sun
Journal:  Microbiol Spectr       Date:  2022-06-06

7.  Newcastle disease virus-based H5 influenza vaccine protects chickens from lethal challenge with a highly pathogenic H5N2 avian influenza virus.

Authors:  Jingjiao Ma; Jinhwa Lee; Haixia Liu; Ignacio Mena; A Sally Davis; Sun Young Sunwoo; Yuekun Lang; Michael Duff; Igor Morozov; Yuhao Li; Jianmei Yang; Adolfo García-Sastre; Juergen A Richt; Wenjun Ma
Journal:  NPJ Vaccines       Date:  2017-12-04       Impact factor: 7.344

8.  Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.

Authors:  Anton Oseledchyk; Jacob M Ricca; Mathieu Gigoux; Brian Ko; Gil Redelman-Sidi; Tyler Walther; Cailian Liu; Gopa Iyer; Taha Merghoub; Jedd D Wolchok; Dmitriy Zamarin
Journal:  Oncotarget       Date:  2018-06-19

9.  Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.

Authors:  Lisa A Santry; Thomas M McAusland; Leonardo Susta; Geoffrey A Wood; Pierre P Major; Jim J Petrik; Byram W Bridle; Sarah K Wootton
Journal:  Mol Ther Methods Clin Dev       Date:  2017-10-16       Impact factor: 6.698

10.  Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.

Authors:  Noemi García-Romero; Irina Palacín-Aliana; Susana Esteban-Rubio; Rodrigo Madurga; Sergio Rius-Rocabert; Josefa Carrión-Navarro; Jesús Presa; Sara Cuadrado-Castano; Pilar Sánchez-Gómez; Adolfo García-Sastre; Estanislao Nistal-Villan; Angel Ayuso-Sacido
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.